Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0278 in Moderate to Severe Atopic Dermatitis
NCT07175233Phase 2Not yet recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Oct 2025
- Primary completion
- Aug 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of SIM0278 in atopic dermatitis (AD), sponsored by Simcere Pharmaceutical Group. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
SIM0278
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07175233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07175233.